Proteasome inhibition has been recognized as a novel treatment modality in hematologic
malignancies. Initially, the reversible proteasome inhibitor bortezomib demonstrated efficacy …

Acute myeloid leukemia (AML) is deadly hematologic malignancy. Despite a well-
characterized genetic and molecular landscape, targeted therapies for AML have failed to …

Many cellular processes converge on the proteasome, and its key regulatory role is
increasingly being recognized. Proteasome inhibition allows the manipulation of many …

Introduction: Proteasome inhibitors have garnered interest as novel chemotherapeutic
agents based on their ability to inhibit the growth of cancer cells by altering the balance of …

The intracellular concentration of proteins in both normal and tumor cells are regulated by
the balance between the rates of protein synthesis vs. degradation. The ubiquitin …

Background: The ubiquitin-proteasome system has become a promising novel molecular
target in cancer due to its critical role in cellular protein degradation, its interaction with cell …

Following its success in multiple myeloma (MM), proteasome inhibition has become a topic
of interest as novel treatment strategy of cancer. By simultaneously affecting multiple …

Acute lymphoblastic leukaemia (ALL) is an aggressive haematolymphoid malignancy. The
prognosis of ALL is excellent in paediatric population, however the outcome of …

The clinical efficacy of proteasome inhibitors in the treatment of multiple myeloma has
encouraged application of proteasome inhibitor containing therapeutic interventions in …

The proteasome inhibitor bortezomib (VELCADE™; formerly PS-341, LDP-341, MLN341) is
a novel dipeptide boronic acid. In cell culture and xenograft models, bortezomib showed …